Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 21, 2024
Event: Entry into a Material Definitive Agreement and Unregistered Sales of Equity Securities.
The Company executed a "January Private Placement" on January 21, 2024, fulfilling obligations under a Side Letter dated July 21, 2023. This transaction involves the issuance of Future Advance Convertible Promissory Notes and Common Stock Purchase Warrants to accredited investors who previously purchased Asset-Backed Secured Promissory Notes (ABL Notes) in July 2023.
Key Financial Metrics and Transaction Details
- Principal Amount: Approximately $4.6 million in Future Advance Convertible Promissory Notes issued.
- Cash Proceeds: $0. The Company received no cash proceeds in the January Private Placement.
- Interest Rate: 15% per annum on outstanding principal.
- Conversion Price: $0.04 per share (subject to adjustment, with a floor of $0.01).
- Warrants Issued:
- 113.9 million shares at an exercise price of $0.067 per share (First Warrants).
- 113.9 million shares at an exercise price of $0.04 per share (Second Warrants).
- Warrant Term: Five years.
- Subordination: Rights under the Notes are subordinate to NH Expansion Credit Fund Holdings LP.
Material Changes and Agreements
This filing represents a material change in the Company's capital structure and debt obligations, transitioning from the maturity of the July 2023 ABL Notes to new convertible instruments.
- Security Agreement: Entered into to secure obligations under the Notes.
- Registration Rights: The Company agreed to file a registration statement within 60 days and have it become effective within 180 days to register the resale of shares issuable upon conversion or exercise.
- Waivers: Purchasers waived obligations regarding a reverse stock split, share reserve amendments, and immediate registration rights through December 31, 2024.
- Letter Agreement (October 2023): Purchasers agreed to exchange Notes and Warrants for common stock immediately prior to the closing of a planned business combination with SEP Acquisition Corp. (SEPA).
- Notes exchanged at $0.04 per share.
- $0.04 Warrants exchanged at 0.9 shares per warrant.
- $0.067 Warrants exchanged at 0.85 shares per warrant.
Outlook, Risks, and Contingencies
Business Combination: The transaction is closely tied to a proposed merger with SEP Acquisition Corp. (SEPA). The filing contains forward-looking statements regarding the closing of this merger.
Key Risks and Contingencies:
- Merger Conditions: Closing requires SEPA to have at least $12.0 million at closing from non-redeemed stock and private placement proceeds.
- Regulatory and Listing: Risks include delays in regulatory approvals and the inability to maintain Nasdaq listing post-transaction.
- Dilution: Significant potential dilution exists due to the issuance of 227.8 million warrant shares and the conversion of $4.6 million in notes at $0.04 per share.
- Forward-Looking Statements: Actual results may differ materially from projections due to economic factors, competitive pressures, and termination of the Merger Agreement.
Investor Verification Checklist
- Verify the status of the proposed merger with SEP Acquisition Corp. (SEPA) and whether the $12.0 million closing condition has been met.
- Confirm the filing and effectiveness of the Registration Statement required within 60 and 180 days, respectively.
- Review the full text of the Letter Agreement to understand the exact mechanics of the debt-to-equity exchange prior to the merger closing.
- Assess the impact of the 15% interest rate and potential conversion on future cash flow and equity dilution.
- Check for any updates on the reverse stock split waiver and its implications for the Company's compliance with exchange listing standards.